INTRODUCTION
The development of high-throughput technologies has had a major influence on uncovering the molecular landscape of tumors and, in acute myeloid leukemia (AML), has revealed a hitherto unrecognized degree of complexity and heterogeneity that presents considerable challenges for the stratification of risk-directed therapy. Whole-genome/exome sequence data from 200 patients with AML showed that the incidence of the majority of recurrently mutated genes detected was less than 10% of all patients, but FLT3 internal tandem duplications (FLT3   ITD   ) and mutations in the NPM1 (NPM1 MUT ) and DNA methyltransferase 3A (DNMT3A MUT ) genes were much more frequent, each occurring in more than 25% of patients. 1 All three mutations predominate in patients with cytogenetically intermediate-risk (IR) AML, and they are often coincident. [2] [3] [4] [5] [6] [7] [8] [9] FLT3 and NPM1 are now routinely screened at diagnosis, with general consensus that FLT3 ITD is associated with an adverse impact and NPM1
MUT with a favorable impact on prognosis, 10,11 and patients with wild-type (WT) FLT3 and NPM1
MUT are not recommended for stem-cell transplantation in first remission.
12, 13 The role of DNMT3A MUT in prognostication is less clear. Although most studies have reported that mutations are associated with worse overall survival (OS), reviewed in recent metaanalyses, 14 ,15 the largest study to date that included 1,060 younger adult patients with IR cytogenetics found that DNMT3A
MUT had no significant impact on survival end points, either overall or in the normal karyotype (NK) subgroup. 9 Furthermore, in studies where an adverse impact has been recorded, there are variable results for the different FLT3/NPM1 genotypic subgroups. [3] [4] [5] [6] [7] 9 Of particular importance to patient management, there is controversy on the impact of the mutations in low-risk patients with IR/NK cytogenetics and FLT3
WT

NPM1
MUT genotype, with studies reporting either no impact 4, 7, 9 or adverse impact. 5, 6 DNMT3A is a DNA methyltransferase that is responsible for de novo methylation of CpG dinucleotides. It has three conserved functional domains, the C-terminal methyltransferase catalytic domain encoded by exons 16 to 23, an N-terminal PWWP domain (exons 8 and 9) that binds to specific lysine residues in methylated histones, and an ADD zinc finger domain (exons 13 to 15) that interacts with nonmethylated H3K4. 16 Mutations were first identified in AML from array-based or whole-genome/exome sequencing of patient samples. 2, 17, 18 Missense mutations at residue R882 are particularly frequent, occurring in approximately two thirds of mutated cases. [2] [3] [4] [5] [6] [7] [8] [9] 18 Other mutations are found throughout the gene, predominantly in exons 13 to 23. They include missense, nonsense, frameshift, and splice site mutations and are usually heterozygous.
There is limited information on the impact of the different mutations, with reports of either no difference between R882 and non-R882 mutations 2, 4, 6, 7 or variable impact in selected groups 8, 9 and no data comparing the impact of missense and truncating mutations, although they may have differing functional consequences. The major R882H mutation disrupts the DNMT3A homodimer interface and acts in a dominant-negative manner, leading to reduced homotetramer formation and much lower catalytic activity. [19] [20] [21] Other missense mutations also occur at the dimer interface, but some are located at the tetramer interface and may have more modest effects on catalytic activity but reduce overall methylation. 22 Truncating mutations, however, are more likely to lead to nonsense-mediated decay 23 and haploinsufficiency than dominant-negative activity. In mouse models, heterozygous Dnmt3a deletion had no apparent effect on phenotype, 24 and primary transplant recipients of Dnmt3a-null hematopoietic stem cells did not have evident changes in hematopoiesis. 25, 26 Furthermore, high-resolution methylation analysis has now shown focal hypomethylation at specific CpG residues in R882-mutated patients that is not seen in the non-R882-mutated patients, with a distinct hierarchical clustering of the R882-mutated patients away from the non-R882-mutated patients. 21 Because knowledge of DNMT3A mutations and their impact on clinical outcome may influence both gene screening strategies and therapy risk stratification, we have screened samples from a large cohort of 914 younger adult IR patients in whom there is extensive follow-up data and evaluated outcome according to the type of DNMT3A mutation detected.
PATIENTS AND METHODS
Patient Cohort
Genomic DNA was available from diagnostic samples of 914 patients with IR cytogenetics, as defined by the Medical Research Council classification, 27 uniformly treated on the United Kingdom Medical Research Council AML10 and AML12 trials between 1988 and 2002; 54% of samples were from bone marrow, 44% were from peripheral blood, and for 2%, the source was not known. Ethical approval for the trials and tissue collection for research was obtained from the Multi-Centre Research Committee of Wales. Informed consent was obtained in accordance with the Declaration of Helsinki. Patient characteristics are listed in Table 1 . Median age at presentation was 43 years (range, 15 to 68 years); only 24 patients (3%) were Ն 60 years old. All samples had known FLT3
ITD and FLT3 tyrosine kinase domain, NPM1, CCAAT/ enhancer binding protein-␣ (CEBPA), and isocitrate dehydrogenase (IDH) 1 and IDH2 genotype. [28] [29] [30] [31] [32] Compared with the 1,996 IR patients treated on these trials who were not included in the study, the investigated patients had significantly higher WBC counts (P Ͻ .001) but no differences in median age, sex, incidence of secondary disease, or proportion who received a stem-cell transplantation in first remission (Appendix Table A1 , online only). The investigated cohort, compared with patients not included in the study, had a borderline higher remission rate (87% v 84%, respectively; P ϭ .03) and better 5-year OS (39% v 34%, respectively; P ϭ .02), but there was no significant difference in cumulative incidence of relapse (CIR; 49% v 53%, respectively; P ϭ .1).
DNMT3A Screening and Mutant Quantification
Amplicons of DNMT3A exons 13 to 23 were screened by denaturing high-performance liquid chromatography (Appendix and Appendix Table  A2 , online only). The common R882H and R882C mutations were confirmed by restriction enzyme digestion; other samples with abnormal chromatograms were sequenced. The relative mutant level for samples with R882H and R882C mutations was quantified using pyrosequencing and expressed as a relative proportion of total DNMT3A alleles.
Statistical Methods and Clinical End Points
Details of the trial protocols have been previously published. 33,34 The AML12 trial is registered at http://www.controlled-trials.com under ISRCTN17833622. Of the 914 patients, 100 underwent allogeneic transplantation from a sibling donor and 17 underwent transplantation from a matched unrelated donor in first remission.
Clinical end points are defined in the Appendix. Mantel-Haenszel and   2 tests were used to test for differences in demographic and clinical data by DNMT3A status. Kaplan-Meier curves were constructed for survival data and compared by means of the log-rank test, with standard tests for heterogeneity between subgroups. 35 Surviving patients were censored on August 9, 2010, with follow-up complete for 98% of patients. Median follow-up was 13.4 years (range, 5.2 to 21.9 years). Multivariable logistic regression analysis was used to find the factors most closely associated with complete remission, and multivariable Cox analysis was used for CIR and OS. Results were adjusted for age, WHO performance status, log(WBC), secondary disease, FLT3 ITD , and NPM1 genotype. Odds ratios or hazard ratios (HRs) and 95% CIs are quoted for end points. In all cases, a ratio of less than 1 indicates benefit for a mutation. All P values are two-tailed.
RESULTS
DNMT3A Mutation Analysis
Overall, 278 mutations were detected in 272 (30%) of 914 patients (Fig 1A and Appendix Table A3 , online only); 175 (63%) were missense R882 mutations. The remaining mutations were distributed throughout the gene and included 63 missense mutations, 37 mutations classified as truncations (12 nonsense, 13 frameshift, 12 at splice sites), and three in-frame deletions. Six patients had homozygous mutations, all except one non-R882 missense substitutions, and six patients had two mutations, all non-R882. Therefore, of the 272 DNMT3A
MUT patients, 175 (64%) had R882 mutations, 59 (22%) had non-R882 missense mutations, 35 (13%) had truncations or in-frame deletions, and three (1%) had two mutations of differing types.
The median DNMT3A mutant level for 172 patients with R882H (n ϭ 123) or R882C (n ϭ 49) mutations was 47% (range, 15% to 85%; Appendix Fig A1, online only) , indicative of a heterozygous mutation in nearly all cells. NPM1
MUT levels were available from 147 of these (7) 18 (7) 13 (7) 5 ( 37 (14) 24 (14) 13 ( 
Missense (7) 36 (13) 25 (14) 11 (11) 8 (14) 3 (9)
IDH2
.01
.003 12 (4) 5 (3) 7 (7) 3 (5) 2 (6) Abbreviations: AML, acute myeloid leukemia; FAB, French-American-British; ITD, internal tandem duplication; MUT, mutant; PS, performance status; RAEB, refractory anemia with excess blasts; RAEB-t, refractory anemia with excess blasts in transformation; TKD, tyrosine kinase domain; WT, wild type.
‫ء‬
Three patients are excluded because they have two mutations of differing types. †Tests are 2 patients, and of the 12 patients with a DNMT3A MUT level less than 35%, nine also had an NPM1
MUT level less than 35% (Fig 1B) . Assuming that an NPM1 mutation is found in virtually all leukemic cells, this suggests that the instances of low-level DNMT3A
MUT were a result of nonleukemic cell contamination rather than the mutation being present only in a subclone of leukemic cells.
Patient Characteristics According to
DNMT3A Genotype
DNMT3A MUT patients were significantly older than DNMT3A WT patients (P Ͻ .001) and more likely to be female (P ϭ .004) and have a higher presenting WBC (P Ͻ .001; Table 1 ). There was a significant difference across morphologic subgroups (P Ͻ .001), with higher rates in M4 (40%) and M5 (43%), which represented 37% and 22%, respectively, of all DNMT3A MUT patients. DNMT3A MUT patients were significantly more likely than DNMT3A
WT patients to have an NK rather than an IR abnormal karyotype (P Ͻ .001). Coincidence with other recurrent mutations showed a positive correlation between DNMT3A
MUT and NPM1
MUT (P Ͻ .001), FLT3 ITD (P Ͻ .001), IDH1 MUT (P ϭ .004), and IDH2
MUT (P ϭ .01), but a negative correlation with CEBPA MUT (P Ͻ .001; Table 1 ; Fig 1C) 
DNMT3A
MUT patients with other mutations (DNMT3A non-R882 ), irrespective of the type of non-R882 mutation (Table 1 ). However, DNMT3A R882 patients had a significantly higher WBC than DNMT3A non-R882 patients (P ϭ .005) and a significantly higher correlation with NPM1 MUT (P ϭ .01). In the DNMT3A Response to Therapy and Long-Term Outcome Stratified According to DNMT3A Genotype There was a slightly but significantly higher remission rate in DNMT3A MUT patients than DNMT3A WT patients (90% v 85%, respectively; P ϭ .03). However, this can probably be attributed to the association with NPM1 MUT , and the significance was not maintained in multivariable analysis taking into account patient characteristics and other molecular markers (odds ratio, 0.74; 95% CI, 0.43 to 1.28; P ϭ .3; Appendix Table A4 , online only). In the total group, neither CIR nor OS differed according to DNMT3A genotype (P ϭ .7 for both; Figs 2A and 2D). However, these results suggesting that DNMT3A mutations are not associated with a poor prognosis must be interpreted with 
MUT patients, in the analysis stratified for NPM1 genotype, the overall impact of DNMT3A
MUT was significantly adverse (HR, 1.35; 95% CI, 1.07 to 1.72; P ϭ .01), and testing for heterogeneity showed that the impact did not significantly differ between NPM1
MUT and NPM1
WT patients (P ϭ .4; Fig 3A) . There was no difference in the Mutant better WT better ITD genotype similarly showed no heterogeneity between the groups of the poor prognostic impact on CIR associated with DNMT3A MUT (P ϭ .7; Fig 3A) . In accord with these results, DNMT3A
MUT patients had worse OS than DNMT3A
WT patients with either NPM1 MUT or NPM1 WT genotype (Figs 2E and 2F), and although not significant for the NPM1
WT
DNMT3A
MUT patients, the overall impact in the stratified analysis was highly significant (HR, 1.37; 95% CI, 1.12 to 1.87; P ϭ .002; Fig 3B) . There was no evidence of heterogeneity of the impact of a DNMT3A mutation between NPM1
MUT and NPM1 WT patients (P ϭ .9) or between the four NPM1/FLT3 ITD genotypes (P ϭ .3; Fig 3B) . Of note, four of the 54 patients with double CEBPA mutations (CEBPA DM ) were also DNMT3A MUT . All four patients attained remission but experienced relapse, which represents a significantly higher CIR compared with CEBPA
DM
DNMT3A
WT patients (P ϭ .03; Fig 3A) . There was also a trend to lower OS in these CEBPA
DM
DNMT3A
MUT patients (P ϭ .1; Fig 3B) .
In multivariable analysis, DNMT3A MUT was a significant adverse risk factor for CIR (HR, 1.27; 95% CI, 1.01 to 1.61; P ϭ .04) and a borderline adverse factor for OS (HR, 1.19; 95% CI, 0.98 to 1.45; P ϭ .1; Appendix Table A4 ). In a forward selection model considering all clinically relevant factors, DNMT3A genotype entered as a significant factor for relapse but not complete remission or OS (Appendix Table  A5 , online only).
Outcome Stratified According to Type of
DNMT3A Mutation
To assess the impact of different DNMT3A mutations, outcome was considered according to the type of mutation-R882, non-R882 Because these results suggested that DNMT3A truncation and missense mutations may differ in their impact on outcome, the data were reanalyzed excluding patients with truncations. The results were comparable to the initial results, but the differences were of slightly greater significance (Figs 5A to 5D ).
DISCUSSION
In this large cohort of cytogenetically IR younger patients with AML, a DNMT3A mutation was associated with poorer prognosis, but this difference was only observed if the results were analyzed separately according to NPM1 genotype, where worse OS was seen in DNMT3A
MUT patients with both NPM1 MUT and NPM1 WT genotype. This is an example of Simpson's paradox. 36 It results from the strong association between DNMT3A and NPM1 mutations and the opposing prognostic impact of the two mutants. In our cohort, 80% of DNMT3A MUT patients were also NPM1
MUT
, which leads to a marked inequality in the proportion of DNMT3A MUT relative proportion of the different genotypic subgroups, the effect that is seen separately in the groups is masked when data from the two groups are combined. This is illustrated in Appendix Table A6 (online  only) . This paradox may explain, at least in part, some of the differences reported to date in studies examining the prognostic impact of DNMT3A mutations, in particular where the genotypic subgroups are small and likely to be less statistically robust. [3] [4] [5] [6] [7] 9 Although there was a significant association between DNMT3A
MUT and FLT3 ITD (41% of DNMT3A MUT patients were FLT3 ITD ), no such differences were observed when DNMT3A
MUT patients were stratified according to FLT3 ITD status because both are associated with poorer outcome. Studies have shown that different mutations within the same gene may be associated with variable patient characteristics and outcome (eg, IDH2 R140 and R172 mutations).
32,37 Therefore, consideration needs to be given to the variety of mutations identified in the DNMT3A gene and their potentially differing functional consequences. In our cohort, 64% of DNMT3A
MUT patients had a mutation at residue R882, comparable to the incidence reported in other studies (mean, 68%; range, 60% to 83%; test for heterogeneity, P ϭ .7).
2,4-9,38
However, the remaining mutations were scattered across the zinc finger and methyltransferase domains and included not only other missense mutations (22% of mutated patients), but also truncations (13%). Analysis in the three mutant categories suggested that, whereas R882 and non-R882 missense mutations were associated with a similar adverse outcome, the truncations seemed to have a different functional impact on the R882 mutations and should be considered as equivalent to DNMT3A
WT from a prognostic standpoint. These data require corroboration from other large cohorts, because there were only 35 patients with a truncation, which therefore results in limited statistical power when split into the NPM1 MUT and NPM1 WT groups. If total loss of protein from the mutated allele leads to haploinsufficiency, then the data are compatible with the lack of impact on hematopoiesis observed for Dnmt3a loss in mouse models, 24-26 rather than the dominantnegative effect that has been demonstrated for the R882 mutant. 20 However, it does raise the issue of the role of such mutations in leukemogenesis, and further studies will be required to investigate this.
For prognostication purposes, combined analysis of the patients with non-R882 missense mutations suggested that they should be considered together with R882-mutated patients as having worse outcome than DNMT3A
WT patients. However, most are unique, and they comprise a highly heterogeneous group of mutations that disrupt different domains of the enzyme. Although both the SIFT and PolyPhen algorithms predict that the majority of mutations in the zinc finger and methyltransferase domains are likely to be deleterious, there is evidence that they differ in their functional and cellular significance. For example, G543 was the second most commonly mutated amino acid, detected in 12 patients (4%). It is close to the histone H3K4 binding surface and does not affect DNA methylation activity but has increased in vitro ability to interact with histone H3. 18 Similarly, differences in mean methylation levels and methylated CpGs have been reported between patients with R882 and non-R882 mutations. 21 More detailed structural and functional analysis of these mutants may thus provide information about the normal roles of DNMT3A and its interactions with other proteins and how disruption of these processes may lead to AML.
From a therapeutic viewpoint, our data confirm that DNMT3A
MUT should be treated as a poor-risk factor. This is of particular relevance to management of patients currently considered as favorable risk, in particular those with CEBPA DM , where DNMT3A
MUT patients were significantly more likely to experience relapse, and those with NPM1
, where the lack of heterogeneity between subgroups indicated that these patients should not be considered differently from the other NPM1/FLT3 genotype groups. The adverse outcome associated with the non-R882 missense mutations also indicates that screening strategies cannot be limited to analysis of exon 23 alone. It is important to note that the need for subgroup analysis in prognostication, as in this case, requires cautious interpretation of the data because of the pitfalls of multiple comparisons and potential bias. The controversy over determining how mutant status should be used for risk stratification, even for the three most commonly mutated genes (DNMT3A, NPM1, and FLT3), reflects the increasing challenge for determining outcome analysis in the face of the extensive genotypic heterogeneity and variable interaction between coincident mutations that is becoming apparent in AML.
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Quantification of Mutant Level
For R882H and R882C mutations, the relative mutant level was quantified using pyrosequencing of biotinylated PCR products prepared using GoTaq Hot Start Polymerase (Promega, Southampton, United Kingdom), 50 cycles of amplification, primers Pyro F and biotinylated Pyro R (Table A2) , and an annealing temperature of 63°C. The 184-bp products were sequenced on a PyroMark MD system (Qiagen, Crawley, United Kingdom) using PyroMark Q96 reagents and protocols (Qiagen) and primer Pyro sequence (Table A2 ). The pyrosequencing software calculated mutant level as a percentage of the total alleles for a particular mutation.
Definition of Clinical End Points
Complete remission (CR) was defined as a normocellular bone marrow containing less than 5% blasts and showing evidence of normal maturation of other marrow elements. CR with incomplete blood count recovery was classified as CR with residual neutropenia or thrombocytopenia. Persistence of myelodysplastic features did not preclude the diagnosis of CR. Remission failures were classified by the clinicians as either a result of induction death (death related to treatment and/or hypoplasia within 30 days of trial entry) or resistant disease (failure to eliminate disease, including partial remission with 5% to 15% blasts in the bone marrow). Where the clinician's evaluation was not available, deaths within 30 days of entry were classified as induction deaths, and deaths later than 30 days after entry were classified as resistant disease. Overall survival was defined as the time from random assignment to death. For patients achieving CR, cumulative incidence of relapse was the incidence of relapse after CR with death in CR as a competing risk. MUT patients multiplied by their survival. For DNMT3A WT , OS ϭ (0.62 ϫ 25%) ϩ (0.38 ϫ 50%) ϭ 34%. For DNMT3A MUT , OS ϭ (0.20 ϫ 15%) ϩ (0.80 ϫ 38%) ϭ 33%. Abbreviations: MUT, mutant; OS, overall survival; WT, wild type.
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